BRIEF-TiGenix says no serious adverse events reported from sepsis challenge trial

jueves 12 de marzo de 2015 02:13 GYT
 

March 12 (Reuters) - TiGenix Nv

* TiGenix completes treatment in phase I sepsis challenge trial with CX611

* Biological effect and safety results to be released 2nd quarter of 2015

* No serious adverse events have been reported Source text for Eikon: Further company coverage: